Aggressive Lymphomas
News
Pembrolizumab sBLA receives priority review
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) for the anti-PD-1...
Conference Coverage
Primary analysis confirms interim findings of CTL019 in DLBCL
ATLANTA—The first chimeric antigen receptor (CAR) T-cell therapy approved in the US to treat children and young adults with leukemia is also...
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
News
Technique may be effective for diagnosing NHL
Preclinical research suggests infrared spectroscopy could be used to diagnose non-Hodgkin lymphoma (NHL). Researchers used mid-infrared...
Conference Coverage
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
Conference Coverage
VTE rates in lenalidomide-treated NHL may warrant prophylaxis
ATLANTA – Lenalidomide as single agent had twice the VTE rate as lenalidomide with a biologic.
Conference Coverage
VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL...
Conference Coverage
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Conference Coverage
Three-month response to CAR T-cells looks durable in DLBCL
ATLANTA – A quarter of the patients in the study were infused as outpatients.
Conference Coverage
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
ATLANTA – Mogamulizumab topped vorinostat in terms of overall response to treatment and on several quality of life scales
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...